Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024

Description

“Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute respiratory distress syndrome (ards) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute respiratory distress syndrome (ards)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acute respiratory distress syndrome (ards) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Diagnosis; Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
3) By Severity: Mild; Moderate; Severe
4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
Companies Mentioned: Johnson & Johnson Services Inc.; Novartis AG; GlaxoSmithKline plc; Medtronic plc; Boehringer Ingelheim International GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Acute Respiratory Distress Syndrome (ARDS) is a potentially life-threatening condition characterized by rigid, non-compliant lungs and inadequate oxygenation. This condition presents as an acute, widespread inflammatory lung injury that can affect critically ill patients. The primary approach to treating ARDS involves employing mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygen levels and minimize further lung damage.

The key facets of dealing with Acute Respiratory Distress Syndrome (ARDS) pertain to its diagnosis and treatment. Diagnosis encompasses the process of distinguishing this condition from other potential disorders and delineating its characteristics. The diagnosis of ARDS typically relies on a physical examination, chest X-ray, and oxygenation levels. ARDS can be triggered by various factors such as COVID-19 (COVID-19 Disease 2019), sepsis, exposure to harmful substances, severe pneumonia, among others, with its severity ranging from mild to moderate and severe. The primary recipients of ARDS-related services include hospitals, clinics, ambulatory service centers, and other healthcare facilities.

The acute respiratory distress syndrome (ARDS) market research report is one of a series of new reports from The Business Research Company that provides acute respiratory distress syndrome (ARDS) market statistics, including acute respiratory distress syndrome (ARDS) industry global market size, regional shares, competitors with an acute respiratory distress syndrome (ARDS) market share, detailed acute respiratory distress syndrome (ARDS) market segments, market trends and opportunities and any further data you may need to thrive in the acute respiratory distress syndrome (ARDS) industry. This acute respiratory distress syndrome (ARDS) market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute respiratory distress syndrome (ards) market size has grown rapidly in recent years. It will grow from $1.17 billion in 2023 to $1.29 billion in 2024 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.

The acute respiratory distress syndrome (ards) market size is expected to see rapid growth in the next few years. It will grow to $1.93 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.

The projected expansion of the acute respiratory distress syndrome (ARDS) market is directly linked to the increasing prevalence of pneumonia. Pneumonia, an infectious condition affecting one or both lungs, results in the accumulation of fluid or pus in the air sacs (alveoli) of the lungs. Pneumonia triggers an inflammatory response within the lungs, leading to heightened blood vessel permeability and the leakage of fluid into the alveoli. This accumulation of fluid disrupts the exchange of oxygen and carbon dioxide, causing respiratory distress. To illustrate, data from the Centers for Disease Control and Prevention in 2021 revealed that pneumonia accounted for 41,309 deaths in the United States, with a mortality rate of 12.4 deaths per 100,000 population. Thus, the escalating prevalence of pneumonia serves as a driving force for the growth of the acute respiratory distress syndrome (ARDS) market.

The upward trajectory in the number of respiratory illnesses is poised to contribute significantly to the expansion of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of medical conditions affecting the respiratory system, including the airways and lungs, often resulting in breathing difficulties. Notably, the surge in respiratory illnesses, exemplified by cases like COVID-19, stands out as a primary catalyst for the growth of the ARDS market. As the prevalence of respiratory illnesses continues to rise, there is a corresponding surge in demand for ARDS treatments and therapies, consequently fostering market growth. As a case in point, a March 2021 report from the Ministry of Health in Chile highlighted that respiratory diseases account for a significant percentage of mortality in Chile, constituting 47% of influenza and pneumonia cases, 3% of chronic lower respiratory tract disorders, and 3% of interstitial respiratory diseases. Additionally, other respiratory ailments make up 5% of all cases. Consequently, the mounting incidence of respiratory illnesses is a driving force behind the growth of the acute respiratory distress syndrome (ARDS) market.

The growth of the acute respiratory distress syndrome (ARDS) market is anticipated to face obstacles due to the considerable expense associated with treatment. The cost of ARDS treatment can be prohibitive, potentially limiting its accessibility to certain patients. This cost encompasses inpatient expenditures, daily ICU costs, and post-hospitalization expenses. As an illustration, in March 2022, the National Library of Medicine reported that mean inpatient ARDS costs in the United States varied from $8,476 to $547,974. Consequently, the elevated cost of treatment serves as a deterrent to the expansion of the acute respiratory distress syndrome (ARDS) market.

Prominent companies operating within the acute respiratory distress syndrome (ARDS) market are dedicating their efforts to the creation of groundbreaking drugs and supplements, including Aviptadil and HSP90 inhibitors, aimed at reinforcing their market position. Aviptadil, a synthetic vasoactive intestinal peptide (VIP), is designed to specifically target receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing company, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, functioning as a vasoactive intestinal peptide supplement, enhances breathing and reduces mortality in ARDS patients. This is achieved through Aviptadil's capacity to safeguard and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis, and suppress interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).

In January 2022, AcelRx Pharmaceuticals Inc., a specialized pharmaceutical company based in the United States, acquired Lowell Therapeutics Inc. for $32.5 million. This strategic acquisition empowers AcelRx Pharmaceuticals to expand its product portfolio and solidify its standing in the pharmaceutical industry. Lowell Therapeutics Inc., also based in the U.S., is a pharmaceutical company dedicated to developing products for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).

Major players in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Drager Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2023. The regions covered in acute respiratory distress syndrome (ARDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12351

1. Executive Summary

2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics

3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies

4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Acute Respiratory Distress Syndrome (ARDS) Market Size and Growth

5.1. Global Acute Respiratory Distress Syndrome (ARDS) Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Acute Respiratory Distress Syndrome (ARDS) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Acute Respiratory Distress Syndrome (ARDS) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acute Respiratory Distress Syndrome (ARDS) Market Segmentation

6.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Diagnosis
Treatment
6.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Coronavirus Disease 2019 (COVID-19)
Sepsis
Inhalation Of Harmful Substances
Severe Pneumonia
Other Causes
6.3. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Mild
Moderate
Severe
6.4. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Ambulatory Service Centers
Other End Users

7. Acute Respiratory Distress Syndrome (ARDS) Market Regional And Country Analysis

7.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market

8.1. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acute Respiratory Distress Syndrome (ARDS) Market

9.1. China Acute Respiratory Distress Syndrome (ARDS) Market Overview
9.2. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acute Respiratory Distress Syndrome (ARDS) Market

10.1. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acute Respiratory Distress Syndrome (ARDS) Market

11.1. Japan Acute Respiratory Distress Syndrome (ARDS) Market Overview
11.2. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acute Respiratory Distress Syndrome (ARDS) Market

12.1. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market

13.1. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acute Respiratory Distress Syndrome (ARDS) Market

14.1. South Korea Acute Respiratory Distress Syndrome (ARDS) Market Overview
14.2. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market

15.1. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
15.2. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acute Respiratory Distress Syndrome (ARDS) Market

16.1. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acute Respiratory Distress Syndrome (ARDS) Market

17.1. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acute Respiratory Distress Syndrome (ARDS) Market

18.1. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acute Respiratory Distress Syndrome (ARDS) Market

19.1. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acute Respiratory Distress Syndrome (ARDS) Market

20.1. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market

21.1. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
21.2. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acute Respiratory Distress Syndrome (ARDS) Market

22.1. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acute Respiratory Distress Syndrome (ARDS) Market

23.1. North America Acute Respiratory Distress Syndrome (ARDS) Market Overview
23.2. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acute Respiratory Distress Syndrome (ARDS) Market

24.1. USA Acute Respiratory Distress Syndrome (ARDS) Market Overview
24.2. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acute Respiratory Distress Syndrome (ARDS) Market

25.1. Canada Acute Respiratory Distress Syndrome (ARDS) Market Overview
25.2. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acute Respiratory Distress Syndrome (ARDS) Market

26.1. South America Acute Respiratory Distress Syndrome (ARDS) Market Overview
26.2. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acute Respiratory Distress Syndrome (ARDS) Market

27.1. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acute Respiratory Distress Syndrome (ARDS) Market

28.1. Middle East Acute Respiratory Distress Syndrome (ARDS) Market Overview
28.2. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acute Respiratory Distress Syndrome (ARDS) Market

29.1. Africa Acute Respiratory Distress Syndrome (ARDS) Market Overview
29.2. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape And Company Profiles

30.1. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape
30.2. Acute Respiratory Distress Syndrome (ARDS) Market Company Profiles
- 30.2.1. Johnson & Johnson Services Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Novartis AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. GlaxoSmithKline plc
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Medtronic plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Boehringer Ingelheim International GmbH
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Acute Respiratory Distress Syndrome (ARDS) Market Other Major And Innovative Companies

31.1. Gilead Sciences Inc.
31.2. Amgen Inc.
31.3. Fresenius SE & Co. KGaA
31.4. Koninklijke Philips N.V.
31.5. Baxter International Inc.
31.6. Teva Pharmaceutical Industries Ltd.
31.7. CSL Behring
31.8. Terumo Corporation
31.9. ResMed Inc.
31.10. Smiths Medical Inc.
31.11. Drager Safety AG & Co. KGaA.
31.12. Getinge AB
31.13. Mallinckrodt plc
31.14. Masimo Corporation
31.15. United Therapeutics Corporation

32. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Benchmarking

33. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market

35. Acute Respiratory Distress Syndrome (ARDS) Market Future Outlook and Potential Analysis

35.1 Acute Respiratory Distress Syndrome (ARDS) Market In 2028 - Countries Offering Most New Opportunities
35.2 Acute Respiratory Distress Syndrome (ARDS) Market In 2028 - Segments Offering Most New Opportunities
35.3 Acute Respiratory Distress Syndrome (ARDS) Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer